Piramal Pharma Receives US FDA Form-483 with Seven Observations for Morpeth Facility
Piramal Pharma Ltd 路 Others (Uncategorized) 路 15 Sept 2026, 1:20 am
Piramal Pharma Receives US FDA Form-483 with Seven Observations for Morpeth Facility The US FDA conducted a GMP inspection at Piramal Pharma鈥檚 Morpeth, UK facility from 3rd Sep'26 to 11th Sep'26, concluding with the issuance of Form-483 containing 7 observations. The observations relate to enhancements in operational practices, procedures, and documentation. Piramal Pharma stated it is actively addressing these points and preparing a detailed response for submission to the US FDA within the stipulated timeline, aiming to resolve all matters in close coordination with the regulator.
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund 路 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 路 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. 路 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. 路 28 Oct 2026
- Please find enclosed Investor presentation for quarter ended 30 September, 2026 路 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 路 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 28 Oct 2026
- Please find enclosed unaudited financial results for Q2 FY 27 路 28 Oct 2026
